|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 1,450.10 INR | -4.03% |
|
-1.23% | -9.88% |
| Jan. 23 | India's Mankind Pharma misses Q3 profit view as expenses jump | RE |
| Jan. 20 | Glenmark Pharmaceuticals Inc., USA Launches Phytonadione Injectable Emulsion USP, 10 Mg/Ml Single Dose Ampules | CI |
| Capitalization | 409B 4.75B 4.52B 4.3B 3.8B 6.8B 7.51B 51.8B 19.02B 169B 17.79B 17.44B 739B | P/E ratio 2025 * |
28.3x | P/E ratio 2026 * | 23x |
|---|---|---|---|---|---|
| Enterprise value | 388B 4.5B 4.28B 4.07B 3.6B 6.44B 7.11B 49.06B 18.02B 160B 16.85B 16.52B 700B | EV / Sales 2025 * |
2.82x | EV / Sales 2026 * | 2.49x |
| Free-Float |
-
| Yield 2025 * |
0.2% | Yield 2026 * | 0.22% |
More valuation ratios
* Estimated data
More news
Last Transcript: Glenmark Pharmaceuticals Limited
More recommendations
More press releases
| 1 day | -4.03% | ||
| 1 week | -1.23% | ||
| Current month | -9.88% | ||
| 1 month | -5.58% | ||
| 3 months | -12.84% | ||
| 6 months | +1.79% | ||
| Current year | -9.88% |
1 week
1 443.50
1 538.55
1 month
1 437.951 658.00
Current year
1 437.951 658.00
1 year
771.001 830.95
3 years
348.501 830.95
5 years
161.651 830.95
10 years
161.651 830.95
| Director | Title | Age | Since |
|---|---|---|---|
| Chief Executive Officer | 55 | 1999-12-31 | |
Indrajit Bose
PSD | President | - | 2023-09-14 |
Ulhas Dhuppad
PSD | President | - | - |
| Manager | Title | Age | Since |
|---|---|---|---|
Cherylann Pinto
BRD | Director/Board Member | 57 | - |
| Chairman | 55 | 2011-05-11 | |
Rajesh V. Desai
BRD | Director/Board Member | 66 | 2007-05-15 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 0.02% | 0 M€ | -4.41% | - | |
| 0.01% | 127 M€ | +3.31% | - |
| Change | 5d. change | 1-year change | 3-years change | Capi. ($) | ||
|---|---|---|---|---|---|---|
| -4.03% | -1.23% | +62.73% | +198.34% | 4.75B | ||
| -0.62% | +2.00% | +33.17% | +125.51% | 50.73B | ||
| +0.70% | +0.55% | +39.07% | +90.48% | 27.62B | ||
| +0.92% | +5.20% | +49.08% | - | 20.8B | ||
| -2.74% | -2.14% | +3.05% | +55.84% | 13.23B | ||
| -3.19% | -3.72% | +30.02% | +142.03% | 11.18B | ||
| -.--% | +0.14% | - | - | 6.79B | ||
| -.--% | -1.95% | - | - | 5.73B | ||
| -0.64% | +4.38% | +35.37% | +34.20% | 5.01B | ||
| -1.05% | -2.80% | +9.47% | +27.22% | 4.88B | ||
| Average | -1.07% | -0.26% | +32.75% | +96.23% | 15.07B | |
| Weighted average by Cap. | -0.61% | +0.87% | +33.86% | +105.95% |
| 2025 * | 2026 * | |
|---|---|---|
| Net sales | 137B 1.59B 1.52B 1.44B 1.28B 2.28B 2.52B 17.39B 6.39B 56.88B 5.97B 5.86B 248B | 152B 1.77B 1.68B 1.6B 1.42B 2.53B 2.8B 19.29B 7.08B 63.09B 6.63B 6.49B 275B |
| Net income | 14.48B 168M 160M 152M 135M 241M 266M 1.83B 673M 5.99B 630M 617M 26.15B | 17.87B 207M 197M 188M 166M 297M 328M 2.26B 831M 7.4B 777M 762M 32.28B |
| Net Debt | -21.64B -251M -239M -227M -201M -360M -397M -2.74B -1.01B -8.96B -941M -922M -39.09B | -29.62B -344M -327M -311M -275M -493M -544M -3.75B -1.38B -12.26B -1.29B -1.26B -53.51B |
More financial data
* Estimated data
Employees
14,989
Sector
Pharmaceuticals
Calendar
2025-02-12
- Q3 2025 Earnings Release (Projected)
| Date | Price | Change | Volume |
|---|---|---|---|
| 25-01-24 | 1,450.10 ₹ | -4.03% | 342,816 |
| 25-01-23 | 1,510.95 ₹ | +0.64% | 277,968 |
| 25-01-22 | 1,501.35 ₹ | +0.12% | 184,505 |
| 25-01-21 | 1,499.50 ₹ | -0.27% | 272,662 |
| 25-01-20 | 1,503.60 ₹ | +2.42% | 377,704 |
Delayed Quote NSE India S.E., January 24, 2025 at 06:49 am EST
More quotes
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
13
Last Close Price
1,450.10INR
Average target price
1,741.46INR
Spread / Average Target
+20.09%
Quarterly revenue - Rate of surprise
- Stock Market
- Equities
- GLENMARK Stock